Previous studies demonstrated that combining the first-generation EGFR-TKI erlotinib with bevacizumab resulted in superior PFS compared to erlotinib alone in advanced NSCLC patients with EGFR mutations (Seto et al., 2014; Yamamoto et al., 2021; Saito et al., 2019; Kawashima et al., 2022; Stinchcombe et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.